What's new

Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 8, Status: Authorised

Mar 25, 2025 - 17:37
 0
Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Abrysvo, Respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 8, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mR...

Next Article

Human medicines European public assessment report (EPAR): Zabdeno, ebola vaccine...

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Litfulo, Ritlecitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0026/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 14, 2025  0

List of withdrawn medicinal products in accordance with...

Mar 7, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Uplizna, Inebilizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Nervous system disorders, PIP number: P/0471/2023

Opinion/decision on a Paediatric investigation plan (PI...

Mar 7, 2025  0